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Background: Hashimoto’s thyroiditis is the most common endocrinopathy in premenopausal women, and is
associated with various gynecological problems, including recurrent miscarriage and unexplained infertility. A
possible influence of Hashimoto’s thyroiditis on the success of intrauterine insemination seems likely, but has not
been evaluated as yet. Therefore, the aim of our study was to retrospectively analyze the impact on intrauterine
insemination outcome of thyroid function and markers suggestive for Hashimoto’s thyroiditis.
Methods: Retrospective cohort study in a tertiary care center of 540 women who underwent Intrauterine
Insemination. The clinical pregnancy rate was the main outcome parameters. The following possible influencing
factors were tested: thyroid-stimulating hormone (TSH); thyroid autoantibodies; age; body mass index; type of
sterility (primary/secondary); parity; male factor; presence of PCO syndrome; ovulation induction; ovarian stimulation;
and current thyroid medication.
Results: The overall clinical pregnancy rate was 6.9% (37/540). Age, thyroid hormone supplementation for thyroid-
stimulating hormone (TSH) levels > 2.5 micro-IU/ml, and ovulation induction with HCG were significantly predictive
in the multivariate analysis (p < 0.05) as influencing factors for the pregnancy rate after intrauterine insemination.
Conclusions: Women undergoing intrauterine insemination seem to benefit from a strict thyroid hormone
supplementation regimen in order to achieve lower TSH levels.
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Intrauterine insemination (IUI) is a simple treatment op-
tion for patients with infertility. In detail, a 0.2-0.5 ml
processed sperm suspension is deposited with a small
catheter transcervically in the uterus, usually without
imaging guidance [1]. Clomifene citrate (CC) is often
used for ovarian stimulation, and Human Choriogonado-
tropin (HCG) can be administered intramuscularly to in-
duce ovulation. IUI results in mean pregnancy rates of
10-20% per patient. However, it can vary individually
from 5-70%, depending on the indication, which might
often be infertility of unknown origin (unexplained infer-
tility) or slightly poor sperm quality [2].* Correspondence: johannes.ott@meduniwien.ac.at
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unless otherwise stated.Hashimoto’s thyroiditis (HT), a chronic autoimmune
thyroiditis, is the most common endocrinopathy in pre-
menopausal women in developed countries, with an inci-
dence of 5-10%, and is the most frequent cause of
subclinical hypothyroidism in women in iodine-sufficient
areas. Worldwide, iodine deficiency is still the most preva-
lent cause of thyroid dysfunction [3,4]. Typically, these
women show elevated levels of antibodies against thyro-
peroxidase (TPO-Ab). Various studies have demonstrated
that HT is associated with various gynecological problems.
These include recurrent miscarriage [5-12]; otherwise un-
explained infertility, defined by the absence of pregnancy
after one year of sexual intercourse without contra-
ception [12]; in vitro fertilization failure [13]; and resist-
ance against CC stimulation in women with polycystic
ovary syndrome (PCO-S) [14].
Moreover, the relationship between thyroid dysfunc-
tion and negative outcomes for the mother in terms oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as for child in terms of decreased intelligence quotient
and birth weight is relatively well known [15,16]. Even
subclinical hypothyroidism without thyroid autoanti-
bodies seems to be associated with the above mentioned
problems [16-19]. Treatment of overt hypothyroidism
during pregnancy is, therefore, mandatory and consists
of levothyroxine therapy adjusted to achieve normal
trimester-specific serum levels of thyroid stimulating
hormone (TSH). In addition to the fact that recommen-
dations for treatment of subclinical hypothyroidism be-
fore and during pregnancy differ among professional
organisations, a vigorous debate is ongoing on the pros
and cons of universal screening for thyroid disease dur-
ing pregnancy versus targeted case finding [20].
The influence of HT and thyroid hypofunction on IUI
success has never been examined. We, thus, aimed to
retrospectively evaluate a possible association between
TPO-Ab levels and thyroid function parameters with re-
gard to IUI outcome.
Methods
In a retrospective cohort study, we included all 540 pa-
tients who underwent an IUI at the Clinical Department
of Gynecologic Endocrinology and Reproductive Medicine
of the Medical University of Vienna, Austria, from January
2008 to December 2011. None of the women revealed any
additional severe endocrine diseases including adrenogen-
ital syndrome, Cushing’s syndrome and others. Thus, no
patients had to be excluded. The study was approved by
the Institutional Review Board of the Medical University
of Vienna (IRB number: 1751/2012). The indications, the
whole proceeding and the assessment for the quality of
semen were in accordance with the international guide-
lines for IUI [1].
Outcome parameters and evaluated predictive factors
Data were retrieved by retrospective chart review. The
primary outcome parameter after IUI was the (clinical)
pregnancy rate diagnosed by ultrasound (positive heart
rate). The following parameters were analyzed as pos-
sible influencing factors on IUI outcome: TSH; TPO-Ab;
thyroglobulin antibodies (TG-Ab); patients’ age; body
mass index (BMI); type of sterility (primary/secondary);
parity; male factor; presence of PCO syndrome; metfor-
min treatment for PCO syndrome; ovulation induction
with HCG; CC stimulation; and current thyroid medica-
tion due to either (i) overt hypothyroidism (defined as
TSH and (total) levothyroxin (T4) > 5.0 μIU/ml and <
64.5 nmol/l, respectively, at any time, or if the woman
was under treatment with thyroid hormone supplementa-
tion due to overt hypothyroidism as defined above; if
women were pre-treated, medical records providing TSH
and T4 levels were obtained in order to verify the diagnosisof overt hypothyroidism), or (ii) subclinical hypothyroidism
defined as TSH > 2.5 μIU/ml according to recent guide-
lines [15]. Notably, all patients who received thyroid hor-
mone supplementation, regardless of whether this was due
to overt or subclinical hypothyroidism, revealed a TSH
level < 2.5 IU/mL at the time of insemination.
All serum parameters included in this analysis were
obtained on the 3rd to the 5th day of the menstrual cycle
with IUI. In our department, the normal range for TSH
is 0.44–3.77 mU/ml, 0–34 IU/ml for anti-TPO antibodies,
and 0–33 IU/ml for TG-Ab. These normal ranges had
been calculated by the laboratory and all examined serum
parameters were determined in the ISO-certified central
laboratory of the General Hospital of Vienna, Vienna,
Austria using commercially available assays (TSH: REF
11731459, measuring range 0.005-100 μIU/ml, Anti-TG:
REF 06368697, measuring range 10.0-4000 IU/ml, Anti-
TPO: REF 06368590, measuring range 5.0-600 IU/ml,
cobas, Roche, Germany).
Statistical analysis
Nominal variables are reported as numbers and frequen-
cies, and continuous variables as medians and interquartile
ranges (IQR). Statistical analysis was accomplished using
(i) Wilcoxon-Mann-Whitney-tests for metric variables,
(ii) chi-square- or Fisher’s exact tests for parametric vari-
ables, and (iii) a logistic regression model with Wald’s tests
to test the statistical significance of all coefficients. Odds
ratios (OR) are given, including the 95 per cent confidence
interval (95% CI). P-values < 0.05 were considered statisti-
cally significant. Statistical analyses were performed with
the SPSS software package, version 19 (SPSS, Chicago).
Results
Detailed patient characteristics are provided in Table 1.
There were no cases of hyperthyroidism. The clinical
pregnancy rate was 6.9% (37/540). We focused on pre-
dictive factors for pregnancy (Table 2). In a univariate
analysis, several parameters were found to be associated
with a lower chance to achieve a pregnancy after IUI,
namely, increasing age, TPO-Ab and TG-Ab levels above
the upper level of normal, the need for thyroid medica-
tion due to overt hypothyroidism, and the presence of a
male factor. In contrast, thyroid hormone supplementa-
tion for TSH levels exceeding the threshold of 2.5 μIU/ml,
and CC stimulation and ovulation induction with HCG
were associated with higher pregnancy rates. When these
factors were tested in a multivariate analysis, only age
(odds ratio 0.94, 95% CI 0.87-0.99), thyroid hormone
supplementation for TSH levels exceeding the thresh-
old of 2.5 μIU/ml (odds ratio 3.31, 95% CI 1.31-8.35),
and ovulation induction with HCG (odds ratio 5.37,
95% CI 1.72-16.69) remained significantly predictive
(p < 0.05; Table 2).
Table 1 Patient characteristics
Characteristics
Age (years)a 34 (29-39)
Body mass index (kg/m2)a 22.9 (20.3-26.0)
Primary infertilityb 277 (51.3)
Parityb 0 (0-0)
TSH (μU/ml)a 1.6 (1.2-2.3)
TPO-Ab (IU/ml)a 0.0 (0-6)
TPO-Ab > upper level of normalb 61 (11.3)
TG-Ab (IU/ml)a 0.0 (0-22)
TG-Ab > upper level of normalb 107 (19.8)
Thyroid medication for overt hypothyroidismb 97 (18.0)
Thyroid medication TSH > 2.5 μIU/mlb 71 (13.1)
Unilateral tubal factorb 42 (7.8)
Presence of PCO-Sc 89 (16.5)
Metformin treatmentb 34 (6.3)
Clomifen citrate stimulationb 165 (30.6)
Ovulation induction with HCGa 266 (49.3)
Endometrial thicknessa 9.0 (8-10)
Male factorb 282 (52.2)
Data are provided as amedian (interquartile ranges) or bnumber (frequencies).





Age (years)b 30 (30-35) 34 (2
Body mass index (kg/m2)b 20.9 (19.9-27.0) 22.9 (20
Primary infertility (vs. secondary infertility)c 19 (51.4) 258 (
Parityc 0 (0-1) 0 (0
TSH (μIU/ml)b 1.6 (1.1-2.2) 1.9 (1.
TPO-Ab > upper level of normalc 0 (0) 61 (1
TG-Ab > upper level of normalc 2 (5.4) 105 (
Thyroid medication for overt hypothyroidismc 2 (5.4) 95 (1
Thyroid medication TSH > 2.5 μIU/mlc 16 (43.2) 55 (1
Presence of PCO-Sc 8 (21.6) 81 (1
Metformin treatmentb 3 (8.1) 31 (
Clomifen citrate stimulationc 19 (51.4) 146 (
Number of IUI treatment cycleb 1 (1-1) 1 (1
Ovulation induction with HCGc 27 (73.0) 239 (
Endometrial thicknessb 10 (8-11) 8 (9
Male factorc 13 (35.1) 269 (
aOR = odds ratio, 95% CI = 95% confidence interval.
bContinuous variable, provided in median (interquartile range).
cNominal variable, provided in n (%).
dItalic numbers in p columns indicate statistical significance.
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with thyroid medication for TSH levels exceeding the
threshold of 2.5 μIU/ml (n = 71) and patients without
any thyroid medication (n = 372). Patients who received
thyroid hormone supplementation for initial TSH levels >
2.5 μIU/ml achieved pregnancy and revealed increased
TPO-Ab and TG-Ab levels as well as polycystic ovary syn-
drome significantly more often (see Table 3). In a next
step, patients with thyroid medication for TSH levels > 2.5
μIU/ml (n = 71) were compared to patients with thyroid
medication for overt hypothyroidism (n = 97; Table 3).
The latter were significantly older and revealed elevated
TPO-Ab levels more often as well as a lower pregnancy
rate.
Finally, we compared TSH levels before IUI in women
with elevated (n = 61) and normal TPO-Ab levels (n = 479;
1.9 μIU/ml IQR 1.2-2.3 vs. 1.6 μIU/ml, IQR 1.1-2.0, respect-
ively; p = 0.032) and in women with elevated (n = 107) and
normal TG-Ab levels (n = 433; 1.5 μIU/ml, IQR 1.2-1.9 vs.
1.5 μIU/ml, IQR 1.2-2.0, respectively; p = 0.845).
Discussion
The main findings of this retrospective study were the
differences between the rates of IUI patients who re-
ceived thyroid hormone supplementation for TSH levels
exceeding the threshold of 2.5 μIU/ml in the pregnancy
and the non-pregnancy groups. The rationale was to
avoid any kind of subclinical hypothyroidism. The factnancy
503)
Univariate analysis Multivariate analysis
OR (95% CI)a p OR (95% CI)a p
9-39) 0.92 (0.87;0.98) 0.015d 0.94 (0.87;0.99) 0.049d
.4-26.0) 1.02 (0.93;1.07) 0.931 - -
51.3) 1.00 (0.95;1.05) 0.861 - -
-0) 1.01 (0.60;1.71) 0.954 - -
2-2.4) 0.89 (0.46;1.21) 0.556 - -
2.1) 0.07 (0.05;0.10) 0.015d 0 (0;inf) 0.997
20.9) 0.22 (0.05;0.91) 0.037d 0.87 (0.19;4.03) 0.861
8.9) 0.25 (0.06;1.04) 0.036d 0.54 (0.12;2.47) 0.338
0.9) 6.94 (3.60;13.40) <0.001d 3.31 (1.31;8.35) 0.009d
6.1) 0.71 (0.31;1.60) 0.407 - -
6.2) 1.34 (0.31;4.92) 0.500 - -
29.0) 0.39 (0.20;0.77) 0.006d 0.77 (0.32;1.85) 0.629
-1) 0.90 (0.59;1.37) 0.638 - -
47.5) 2.95 (1.40;6.22) 0.005d 5.37 (1.72;16.69) 0.004d
-10) 1.09 (0.91;1.31) 0.324 - -
53.5) 0.47 (0.23;0.95) 0.034d 0.60 (0.27;1.03) 0.067
Table 3 Comparison of patients with thyroid medication for TSH levels exceeding the threshold of 2.5 μIU/ml and
patients without any thyroid medication
Thyroid medication
for TSH levels
No thyroid medication Thyroid medication for
overt hypothyroidism
pd pe
> 2.5 μIU/ml (n = 71) (n = 372) (n = 97)
Age (years)a 33 (27-40) 33 (28-39) 34 (30-39) 0.324 0.047c
Body mass index (kg/m2)a 22.3 (19.4-25.1) 22.9 (20.3-26.7) 23.1 (21.4—25.1) 0.260 0.340
Primary infertility (vs. secondary infertility)b 36 (50.7) 202 (54.3) 39 (40.2) 0.578 0.176
Parityb 0 (0-1) 0 (0-1) 0 (0-1) 0.961 0.667
TSH (μIU/ml)a 1.6 (1.1-2.2) 1.5 (1.1-2.0) 1.4 (0.4-2.2) 0.422 0.107
TPO-Ab > upper level of normalb 8 (11.3) 14 (3.8) 39 (40.2) 0.014c < 0.001c
TG-Ab > upper level of normalb 22 (31.0) 57 (15.3) 28 (28.9) 0.004c 0.767
Presence of PCO-Sb 16 (22.5) 56 (15.1) 17 (17.5) < 0.001c 0.419
Metformin treatmentb 5 (7.0) 19 (5.1) 10 (10.3) 0.565 0.588
Clomifen citrate stimulationb 23 (32.4) 115 (30.9) 27 (27.8) 0.805 0.523
Number of IUI treatment cyclea 1 (1-1) 1 (1-1) 1 (1-1) 0.063 0.598
Ovulation induction with HCGb 36 (50.7) 181 (48.7) 49 (50.5) 0.752 0.981
Endometrial thicknessa 9 (8-10) 9 (8-10) 9 (8-10) 0.866 0.864
Male factorb 35 (49.3) 195 (52.4) 52 (53.6) 0.629 0.581
Pregnancy rateb 16 (23.9) 19 (5.1) 2 (2.1) < 0.001c < 0.001c
Patients with overt hypothyroidism were excluded for this analysis.
aContinuous variable, provided in median (interquartile range).
bNominal variable, provided in n (%).
cItalic letters indicate statistical significance.
dComparison of patients with thyroid medication for TSH levels > 2.5 μIU/ml and patients without thyroid medication.
eComparison of patients with thyroid medication for TSH levels > 2.5 μIU/ml and patients with thyroid medication for overt hypothyroidism.
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pregnant after IUI when they were compared to patients
without any thyroid hormone supplementation (Table 3)
is one of the key findings of our study.
Notably, despite the lower pregnancy rate in patients
with thyroid hormone supplementation for overt
hypothyroidism than in those with supplementation for
subclinical hypothyroidism, which can be explained by the
lower age in the latter group (Table 3), a patient’s need for
thyroid medication due to overt hypothyroidism was not a
significant influence on IUI outcome in the multivariate
model. This is in accordance with a recent study in IVF
patients demonstrating that adequate levothyroxine treat-
ment may overcome the detrimental effects of overt
hypothyroidism [21]. These results were quite contradict-
ory to a previous report suggesting the opposite [22].
When comparing the reports, it seems evident that in the
study by Busnelli et al., thyrotropin serum levels below
2.5 μIU/ml were maintained, in contrast to a higher
threshold of <4.0 μIU/ml in the study by Scoccia et al.
These valuable results are supported by our data. Obvi-
ously, infertile women undergoing reproductive medicine
procedures benefit from a more generous supplementa-
tion with levothyroxine, even in absence of overt
hypothyroidism. A recent randomized study has demon-
strated that levothyroxine treatment improved embryoquality and pregnancy outcome in subclinical hypothyroid
women undergoing IVF [23].
One might argue that, in our study, in women who did
not suffer from overt hypothyroidism, but who received
thyroid supplementation for subclinical hypothyroidism
with TSH levels > 2.5 μIU/ml, TSH levels might have been
suppressed even more than in non-supplemented women.
Hypothetically, this mechanism might have contributed to
the increased pregnancy rates. However, we did not ob-
serve a difference in TSH levels on the 3rd to the 5th day
of the menstrual cycle with IUI, neither in the multivariate
model (Table 2) nor in the comparison of patients accord-
ing to the type of thyroid hormone supplementation (for
subclinical hypothyroidism/for overt hypothyroidism/
patients without thyroid hormone supplementation;
(Table 3). One could argue that thyroid hormone sup-
plementation overcame fluctuations in thyroid hormone
levels or other unknown effects that might have been due
to HT [24]. This hypothesis is based on the following con-
siderations: patients who were in need for thyroid hor-
mone supplementation due to TSH levels > 2.5 μIU/ml
revealed significantly more often increased thyroid auto-
antibody levels than patients who did not receive thyroid
hormones at all (Table 3). This finding confirms the link
between HT and subclinical hypothyroidism in our patient
population. HT has been frequently discussed as a factor
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ment [5,10,12,13]. However, higher anti-thyroid anti-
bodies indicative of HT were associated with IUI failure
after univariate analysis, but did not remain significant
after multivariate analysis, in contrast to subclinical
hypothyroidism treated with levothyroxine supplementa-
tion (Table 2). This suggests that (i) not HT – the most
common cause of hypothyroidism in iodine-sufficient
areas [3,4] – but rather, hypothyroidism itself is the more
important thyroid factor that influences IUI outcome and
(ii) thyroid hormone supplementation ameliorates hidden
effects of HT on thyroid hormone levels. This is also sup-
ported by the fact that we found lower TSH levels in
patients with than patients without elevated TPO-Ab des-
pite the fact all women revealed TSH level < 2.5 μIU/ml at
the time of IUI. However, it is unlikely that this explains
the whole positive influence of thyroid hormone supple-
mentation on pregnancy rates in our study. We find it
hard to provide further explanations. It is evident that fu-
ture studies are warranted to clarify the value of generous
levothyroxine supplementation and the threshold that
should be used to discriminate between infertile women
in need and those not in need of such a treatment. More-
over, the difference between the upper limit of normal
provided by the laboratory and the threshold considered
to give levothyroxine supplementation in infertile women
needs to be emphasized. This suggests that a specific
range for women who plan to undergo assisted reproduct-
ive procedures could be needed in the future.
In addition to the above mentioned findings and con-
siderations, the comparison of patients without any thy-
roid medication and patients with thyroid medication
for TSH > 2.5 μIU/ml (Table 3) revealed that the latter
achieved pregnancy more often and suffered from PCO-
S more often. A previous report has already demon-
strated a three-fold higher incidence of autoimmune thy-
roid diseases in women with PCO-S than in the general
female population [25]. However, as demonstrated in
Table 2, PCO-S did not independently contribute to the
pregnancy rates after IUI.
Notably, ovulation induction with HCG was another
factor that was significantly associated with clinical preg-
nancy after IUI. This is in accordance with previous
studies [26,27]. After multivariate analysis, the parameter
“male factor” differed only by trend (p = 0.067) between
patients who achieved a clinical pregnancy and those
who did not. This is likely due to the small number of
patients in the pregnancy group. The presence of a male
factor has frequently been reported as an influencing
parameter on IUI outcome [28].
The study must be interpreted within its limitations:
(i) its retrospective design; and (ii) the low pregnancy
rate, which resulted in a small number of patients in the
pregnancy group. In our study, the clinical pregnancyrate after IUI was 6.9%. This is comparatively low com-
pared to the literature, which reports rates of about
10-20% [2,29]. Notably, in our department, many IUI
procedures were performed according to the patient’s
desire. This was the case for couples who could not afford
an IVF treatment and opted for IUI, for example, in cases
of infertility due to a moderate male factor, and for women
aged 40 years or older. The latter is also highlighted by
age distribution, as demonstrated in Table 2. Women who
did not achieve pregnancy had a median age of 34 years,
with an upper IQR level of 39. Moreover, increasing age
remained a significant risk factor for IUI failure after
multivariate analysis. This is in accordance with previous
studies [29-32]. (iii) One of the most common reasons for
hypothyroidism is iodine deficiency. Unfortunately, we
cannot provide data on iodine status in our patients. How-
ever, since the second iodine prophylaxis, Austria is
not to be considered a region of iodine deficiency any
more. Moreover, all our patients were recommended to
use common micronutrient supplementation prepara-
tions. These always include at least 100 μg iodine per day.
Nonetheless, the lack of data on iodine status has to be
considered a study limitation.
Conclusions
Our study provides the following key findings: (i) “classic”
predictive factors for IUI outcome, including age, ovula-
tion induction with HCG and – although only differing by
trend –the presence of a male factor were confirmed;
(ii) women with overt hypothyroidism who received thy-
roid hormone supplementation that was sufficient to keep
TSH levels < 2.5 μIU/ml were not at greater risk of IUI
failure; and (iii) for women who received thyroid hormone
supplementation due to subclinical hypothyroidism, with
TSH levels > 2.5 μIU/ml, higher pregnancy rates were
found after IUI. These findings suggest that women
undergoing IUI, and, hypothetically, also other medical in-
terventions for infertility, benefit from a strict thyroid hor-
mone supplementation in order to achieve lower TSH
levels. Although our study sheds new light on the issue of
the influence of thyroid function and thyroid supplemen-
tation on IUI success, prospective studies are needed to
confirm our results. Future work should also clarify
whether the TSH threshold for thyroid hormone supple-
mentation should be decreased for infertile women.
Competing interests
All authors declare that there are no potential conflicts of interest, whether
of a financial or other nature.
Authors' contributions
All authors contributed to the writing process of the manuscript and
approved the final version. BJ and JO were the principal investigators, wrote the
study protocol and manuscript. AP, EV, KM and RP worked as co-investigators
performed the literature search and were crucially involved in data
interpretation. All authors read and approved the final manuscript.
Jatzko et al. Reproductive Biology and Endocrinology 2014, 12:28 Page 6 of 6
http://www.rbej.com/content/12/1/28Author details
1Department of Obstetrics and Gynecology, Clinical Department of
Gynecologic Endocrinology and Reproductive Medicine, Medical University
of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. 2Department of
Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna,
Austria.
Received: 4 February 2014 Accepted: 31 March 2014
Published: 5 April 2014References
1. The ESHRE Capri Workshop Group: Intrauterine insemination. Hum Reprod
Update 2009, 15:265–277.
2. Abdelkader AM, Yeh J: The potential use of intrauterine insemination as a
basic option for infertility: a review for technology-limited medical
settings. Obstet Gynecol Int 2009, 2009:584837.
3. Hayashi N, Tamaki N, Konishi J, Yonekura Y, Senda M, Kasagi K: Sonography
of Hashimoto’s thyroiditis. J Clin Ultrasound 1986, 14:123–126.
4. Peterson CM: Thyroid disease and fertility. Immunol Allerg Clin North Am
1994, 14:725–738.
5. Poppe K, Velkeniers B, Glinoer D: Thyroid disease and female
reproduction. Clin Endocrinol (Oxf ) 2007, 66:309–321.
6. Stagnaro Green A, Roman SH, Cobin RH, El Harazy E, Alvarez Marfany M,
Davies TF: Detection of at-risk pregnancy by means of highly sensitive
assays for thyroid autoantibodies. JAMA 1990, 19:1422–1425.
7. Lejeune B, Grun JP, de Nayer P, Servais G, Glinoer D: Antithyroid antibodies
underlying thyroid abnormalities and miscarriage or pregnancy induced
hypertension. Br J Obstet Gynaecol 1993, 100:669–672.
8. Pratt DE, Kaberlein G, Dudkiewicz A, Karande V, Gleicher N: The association
of antithyroid antibodies in euthyroid nonpregnant women with
recurrent first trimester abortions in the next pregnancy. Fertil Steril 1993,
60:1001–1005.
9. Esplin MS, Branch DW, Silver R, Stagnaro-Green A: Thyroid autoantibodies
are not associated with recurrent pregnancy loss. Am J Obstet Gynecol
1988, 179:1583–1586.
10. Bussen S, Steck T, Dietl J: Increased prevalence of thyroid antibodies in
euthyroid women with a history of recurrent in-vitro fertilization failure.
Human Reprod 2000, 15:545–548.
11. Dendrinos S, Papasteriades C, Tarassi K, Christodoulakos G, Prasinos G,
Creatsas G: Thyroid autoimmunity in patients with recurrent spontaneous
miscarriages. Gynecol Endocrinol 2000, 14:270–274.
12. Van den Boogaard E, Vissenberg R, Land JA, van Wely M, van der Post JA,
Goddijn M: Significance of (sub)clinical thyroid dysfunction and thyroid
autoimmunity before conception and in early pregnancy: a systematic
review. Hum Reprod Update 2011, 17:605–619.
13. Geva E, Vardinon N, Lessing JB, Lerner-Geva L, Azem F, Yovel I: Organ-
specific autoantibodies are possible markers for reproductive failure:
a prospective study in an in-vitro fertilization-embryo transfer
programme. Hum Reprod 1996, 11:1627–1631.
14. Ott J, Aust S, Kurz C, Nouri K, Wirth S, Huber JC: Elevated antithyroid
peroxidase antibodies indicating Hashimoto’s thyroiditis are associated
with the treatment response in infertile women with polycystic ovary
syndrome. Fertil Steril 2011, 94:2895–2897.
15. De Groot L1, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH,
Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S:
Management of thyroid dysfunction during pregnancy and postpartum:
an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab
2012, 97:2543–2565.
16. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ: Higher
maternal TSH levels in pregnancy are associated with increased risk for
miscarriage, fetal or neonatal death. Eur J Endocrinol 2009, 160:985–991.
17. Casey BM, Dashe JS, Wells CE, Mclntire DD, Byrd W, Leveno KJ, Cunningham
FG: Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol
2005, 105:239–245.
18. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O’Heir
CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ: Maternal thyroid
deficiency during pregnancy and subsequent neurophysiological
development of the child. N Engl J Med 1999, 341:549–555.
19. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stangaro-Green A:
Increased pregnancy loss rate in thyroid antibody negative women withTSH Levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin
Endocrinol Metab 2010, 95:E44–E48.
20. Vila L, Velasco I, González S, Morales F, Sánchez E, Torrejón S, Soldevila B,
Stagnaro-Green A, Puig-Domingo M: Controversies in endocrinology:
on the need for universal thyroid screening in pregnant women. Eur J
Endocrinol 2013, 170:R17–R30.
21. Busnelli A, Somigliana E, Benaglia L, Leonardi M, Ragni G, Fedele L: In
vitro fertilization outcomes in treated hypothyroidism. Thyroid 2013,
23:1319–1325.
22. Scoccia B, Demir H, Kang Y, Fierro MA, Winston NJ: In vitro fertilization
pregnancy rates in levothyroxine-treated women with hypothyroidism
compared to women without thyroid dysfunction disorders.
Thyroid 2012, 22:631–636.
23. Kim CH, Ahn JW, Kang SP, Kim SH, Chae HD, Kang BM: Effect of
levothyroxine treatment on in vitro fertilization and pregnancy outcome
in infertile women with subclinical hypothyroidism undergoing
in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2011,
95:1650–1654.
24. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M:
Hashimoto’s thyroiditis affects symptom load and quality of life
unrelated to hypothyroidism: a prospective case–control study in
women undergoing thyroidectomy for benign goiter. Thyroid 2011,
21:161–167.
25. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R: High prevalence
of autoimmune thyroiditis in patients with polycystic ovary syndrome.
Eur J Endocrinol 2004, 150:363–369.
26. Gomez R, Schorsch M, Steetskamp J, Hahn T, Heidner K, Seufert R: The
effect of ovarian stimulation on the outcome of intrauterine
insemination. Arch Obstet Gynecol 2014, 289:181–185.
27. Mitwally MF, Abdel-Razeq S, Casper RF: Human chorionic gonadotropin
administration is associated with high pregnancy rates during ovarian
stimulation and timed intercourse or intrauterine insemination.
Reprod Biol Endocrinol 2004, 7:55.
28. Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P: Intra-uterine
insemination for male subfertility. Cochrane Database Syst Rev 2007,
17:CD000360.
29. Jeon YE, Jung JA, Kim HY, Seo SK, Cho S, Choi YS: Predictive factors for
pregnancy during the first four intrauterine insemination cycles using
gonadotropin. Gynecol Endocrinol 2013, 29:834–838.
30. Wiser A, Shalom-Paz E, Reinblatt SL, Son WY, Das M, Tulandi T: Ovarian
stimulation and intrauterine insemination in women aged 40 years or
more. Reprod Biomed Online 2012, 24:170–173.
31. Armstrong S, Akande V: What is the best treatment option for infertile
women aged 40 and over? J Assist Reprod Genet 2013, 30:667–671.
32. Kamath MS, Bhave P, Aleyamma T, Nair R, Chandy A, Mangalaraj AM:
Predictive factors for pregnancy after intrauterine insemination: a
prospective study of factors affecting outcome. J Hum Reprod Sci 2010,
3:129–134.
doi:10.1186/1477-7827-12-28
Cite this article as: Jatzko et al.: The impact of thyroid function on
intrauterine insemination outcome - a retrospective analysis. Reproductive
Biology and Endocrinology 2014 12:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
